Harmony Biosciences Holdings, Inc. Form 8-K Summary
Business Context and Reporting Period
Harmony Biosciences Holdings, Inc. filed a current report on June 9, 2021, with the report signed on June 15, 2021. The filing concerns an executive promotion and related compensation changes at its operating subsidiary, Harmony Biosciences, LLC. The company’s common stock trades on Nasdaq under the symbol HRMY.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
Material Changes Versus the Prior Period
- Jeffrey Dierks was promoted from Senior Vice President and Chief Commercial Officer to Executive Vice President and Chief Commercial Officer of Harmony Biosciences, LLC.
- Effective retroactively as of June 1, 2021, his annual base salary increased to $400,070.
- His target annual bonus increased to 50% of annual base salary.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, business outlook, risk update, contingency disclosure, or unusual operating item. The principal disclosed event is the executive promotion and related compensation adjustment.
Investor Verification Items
- Verify the effective date and terms of Mr. Dierks’ revised compensation.
- Review subsequent filings for additional executive compensation, employment, or organizational changes.
- Consult the company’s periodic financial filings for operating performance, liquidity, debt, and guidance information not included in this Form 8-K.